Key result
Levosimendan is linked to reduced patient mortality across meta-analyses of >6000 patients.
Why the study?
Does levosimendan reduce mortality in patients with acute heart failure and other cardiac conditions?
Meta-Analysis (n=6,000)
Does levosimendan reduce mortality in patients with acute heart failure and other cardiac conditions?
A comprehensive review of 25 meta-analyses and a pooled analysis of regulatory trials consistently demonstrate a mortality benefit for levosimendan across various acute cardiac conditions.
No takes yet. Share an insight, caveat, or question.
Supports levosimendan consideration in acute cardiac conditions; confirms mortality benefit across settings and comparators.
Pollesello et al. (2016) conducted a meta-analysis in acute heart failure and other cardiac conditions (n=6,000). Levosimendan vs. comparator was evaluated on patient mortality. Levosimendan was associated with a significant reduction in patient mortality across 22 of 25 meta-analyses encompassing over 6000 patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: